Home/Filings/4/0000899243-20-023393
4//SEC Filing

Valor IV Pharma Holdings, LLC 4

Accession 0000899243-20-023393

CIK 0001802665other

Filed

Aug 24, 8:00 PM ET

Accepted

Aug 25, 7:41 PM ET

Size

26.5 KB

Accession

0000899243-20-023393

Insider Transaction Report

Form 4
Period: 2020-08-21
Transactions
  • Conversion

    Common Stock

    2020-08-21+240,66813,166,357 total
  • Conversion

    Common Stock

    2020-08-21+12,080,35212,925,688 total
  • Conversion

    Series A Preferred Stock

    2020-08-2177,950,7120 total
    Common Stock (12,080,352 underlying)
  • Conversion

    Series C Preferred Stock

    2020-08-211,810,1260 total
    Common Stock (240,668 underlying)
Transactions
  • Conversion

    Series A Preferred Stock

    2020-08-2177,950,7120 total
    Common Stock (12,080,352 underlying)
  • Conversion

    Common Stock

    2020-08-21+12,080,35212,925,688 total
  • Conversion

    Series C Preferred Stock

    2020-08-211,810,1260 total
    Common Stock (240,668 underlying)
  • Conversion

    Common Stock

    2020-08-21+240,66813,166,357 total
Transactions
  • Conversion

    Series A Preferred Stock

    2020-08-2177,950,7120 total
    Common Stock (12,080,352 underlying)
  • Conversion

    Common Stock

    2020-08-21+240,66813,166,357 total
  • Conversion

    Common Stock

    2020-08-21+12,080,35212,925,688 total
  • Conversion

    Series C Preferred Stock

    2020-08-211,810,1260 total
    Common Stock (240,668 underlying)
Transactions
  • Conversion

    Common Stock

    2020-08-21+12,080,35212,925,688 total
  • Conversion

    Common Stock

    2020-08-21+240,66813,166,357 total
  • Conversion

    Series C Preferred Stock

    2020-08-211,810,1260 total
    Common Stock (240,668 underlying)
  • Conversion

    Series A Preferred Stock

    2020-08-2177,950,7120 total
    Common Stock (12,080,352 underlying)
Transactions
  • Conversion

    Common Stock

    2020-08-21+240,66813,166,357 total
  • Conversion

    Common Stock

    2020-08-21+12,080,35212,925,688 total
  • Conversion

    Series A Preferred Stock

    2020-08-2177,950,7120 total
    Common Stock (12,080,352 underlying)
  • Conversion

    Series C Preferred Stock

    2020-08-211,810,1260 total
    Common Stock (240,668 underlying)
Transactions
  • Conversion

    Common Stock

    2020-08-21+240,66813,166,357 total
  • Conversion

    Series C Preferred Stock

    2020-08-211,810,1260 total
    Common Stock (240,668 underlying)
  • Conversion

    Common Stock

    2020-08-21+12,080,35212,925,688 total
  • Conversion

    Series A Preferred Stock

    2020-08-2177,950,7120 total
    Common Stock (12,080,352 underlying)
Transactions
  • Conversion

    Common Stock

    2020-08-21+12,080,35212,925,688 total
  • Conversion

    Common Stock

    2020-08-21+240,66813,166,357 total
  • Conversion

    Series C Preferred Stock

    2020-08-211,810,1260 total
    Common Stock (240,668 underlying)
  • Conversion

    Series A Preferred Stock

    2020-08-2177,950,7120 total
    Common Stock (12,080,352 underlying)
Transactions
  • Conversion

    Series A Preferred Stock

    2020-08-2177,950,7120 total
    Common Stock (12,080,352 underlying)
  • Conversion

    Series C Preferred Stock

    2020-08-211,810,1260 total
    Common Stock (240,668 underlying)
  • Conversion

    Common Stock

    2020-08-21+12,080,35212,925,688 total
  • Conversion

    Common Stock

    2020-08-21+240,66813,166,357 total
Transactions
  • Conversion

    Common Stock

    2020-08-21+12,080,35212,925,688 total
  • Conversion

    Common Stock

    2020-08-21+240,66813,166,357 total
  • Conversion

    Series A Preferred Stock

    2020-08-2177,950,7120 total
    Common Stock (12,080,352 underlying)
  • Conversion

    Series C Preferred Stock

    2020-08-211,810,1260 total
    Common Stock (240,668 underlying)
Footnotes (4)
  • [F1]Each share of preffered stock automatically converted on a 8.215-for-1 basis into common stock upon the closing of the Issuer's initial public offering.
  • [F2]Antonio Gracias is the Chief Executive Officer of Valor Management L.P. ("Valor Management") and Juan A. Sabater is the President of Valor Management. Valor Management is the managing member of Valor Equity Capital IV LLC, which is the general partner of Valor Equity Associates IV L.P., which, in turn, is the general partner of each of Valor Equity Partners IV L.P., Valor Equity Partners IV-A L.P. and Valor Equity Partners IV-B L.P. (collectively, the "Valor Funds"). The Valor Funds are the sole members of the Valor IV Pharma Holdings, LLC ("Valor"). As such, Messers. Gracias and Sabater may be deemed to beneficially own the shares held by Valor. Each of Messers. Gracias and Sabater disclaims beneficial ownership over the shares described herein except to the extent of their pecuniary interest therein.
  • [F3]Includes 2,950,712 shares received upon the payment of an in-kind dividend on the Series A Preferred Stock on August 21, 2020.
  • [F4]Includes 23,141 shares received upon the payment of an in-kind dividend on the Series C Preferred Stock on August 21, 2020.

Issuer

Harmony Biosciences Holdings, Inc.

CIK 0001802665

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001821186

Filing Metadata

Form type
4
Filed
Aug 24, 8:00 PM ET
Accepted
Aug 25, 7:41 PM ET
Size
26.5 KB